EB-MF-CAR-NK-01 not checked

Beijing Biotech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumor cells and FAPpositive stromal elements, manufactured under GMP”In the company’s words, NCT07510815 on ClinicalTrials.gov
Tested for
Malignant Pleural Mesotheliomas
Main trialPhase 1/2
“This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma. Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.”In the company’s words, NCT07510815 on ClinicalTrials.gov
Other names
Mesothelin/FAP Dual-Target CAR-NK Cells

Other drugs for Malignant Pleural Mesotheliomas

All 28 drugs for Malignant Pleural Mesotheliomas

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 14 Mar 2027 Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow EB-MF-CAR-NK-01

Following is part of Solo: you see every change to EB-MF-CAR-NK-01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in